Mitogen-activated protein kinase 14 is a novel negative regulatory switch for the vascular smooth muscle cell contractile gene program

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 2, 2013, Pages 378-386

  Long, Xiaochun ^a   Cowan, Sarah L ^a   Miano, Joseph M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

differentiation; myocardin; p38 mitogen activated protein kinase; smooth muscle

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOCARDIN; SERUM RESPONSE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CORONARY ARTERY; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ACTIN CYTOSKELETON; ACTINS; ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; BLOTTING, WESTERN; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; CELL DIFFERENTIATION; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENOTYPE; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 14; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; MYOSIN HEAVY CHAINS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RHOA GTP-BINDING PROTEIN; RNA INTERFERENCE; SERUM RESPONSE FACTOR; SIGNAL TRANSDUCTION; TIME FACTORS; TRANS-ACTIVATORS; TRANSFECTION; VASOCONSTRICTION;

EID: 84872926889     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300645     Document Type: Article

References (67)

1. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767-801.
2. Albinsson S, Sessa WC. Can microRNAs control vascular smooth muscle phenotypic modulation and the response to injury? Physiol Genomics. 2011;43:529-533.
3. Alexander MR, Owens GK. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol. 2012;74:13-40.
4. Rong JX, Shapiro M, Trogan E, Fisher EA. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci USA. 2003;100:13531-13536.
5. Tanaka T, Sato H, Doi H, Yoshida CA, Shimizu T, Matsui H, Yamazaki M, Akiyama H, Kawai-Kowase K, Iso T, Komori T, Arai M, Kurabayashi M. Runx2 represses myocardin-mediated differentiation and facilitates osteogenic conversion of vascular smooth muscle cells. Mol Cell Biol. 2008;28:1147-1160.
6. Shen J, Yang M, Jiang H, Ju D, Zheng JP, Xu Z, Liao TD, Li L. Arterial injury promotes medial chondrogenesis in Sm22 knockout mice. Cardiovasc Res 2010.
7. Chow N, Bell RD, Deane R, Streb JW, Chen J, Brooks A, Van Nostrand W, Miano JM, Zlokovic BV. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood fow dysregulation in Alzheimer's phenotype. Proc Natl Acad Sci USA. 2007;104:823-828.
8. Pauletto P, Sarzani R, Rappelli A, Chiavegato A, Pessina AC, Sartore S. Differentiation and growth of vascular smooth muscle cells in experimental hypertension. Am J Hypertens. 1994;7(7 Pt 1):661-674.
9. Xu Q. Stem cells and transplant arteriosclerosis. Circ Res. 2008;102:1011-1024.
10. Miano JM, Berk BC. Retinoids: versatile biological response modifers of vascular smooth muscle phenotype. Circ Res. 2000;87:355-362.
11. Kolodziejska KM, Noyan-Ashraf MH, Nagy A, Bacon A, Frampton J, Xin HB, Kotlikoff MI, Husain M. c-Myb-dependent smooth muscle cell differentiation. Circ Res. 2008;102:554-561.
12. Nishimura G, Manabe I, Tsushima K, Fujiu K, Oishi Y, Imai Y, Maemura K, Miyagishi M, Higashi Y, Kondoh H, Nagai R. DeltaEF1 mediates TGF-beta signaling in vascular smooth muscle cell differentiation. Dev Cell. 2006;11:93-104.
13. Qiu P, Ritchie RP, Fu Z, Cao D, Cumming J, Miano JM, Wang DZ, Li HJ, Li L. Myocardin enhances Smad3-mediated transforming growth factor-beta1 signaling in a CArG box-independent manner: Smad-binding element is an important cis element for SM22alpha transcription in vivo. Circ Res. 2005;97:983-991.
14. Shang Y, Yoshida T, Amendt BA, Martin JF, Owens GK. Pitx2 is functionally important in the early stages of vascular smooth muscle cell differentiation. J Cell Biol. 2008;181:461-473.
15. Pepe AE, Xiao Q, Zampetaki A, Zhang Z, Kobayashi A, Hu Y, Xu Q. Crucial role of nrf3 in smooth muscle cell differentiation from stem cells. Circ Res. 2010;106:870-879.
16. Boucher J, Gridley T, Liaw L. Molecular pathways of notch signaling in vascular smooth muscle cells. Front Physiol. 2012;3:81.
17. Norman C, Runswick M, Pollock R, Treisman R. Isolation and properties of cDNA clones encoding SRF, a transcription factor that binds to the c-fos serum response element. Cell. 1988;55:989-1003.
18. Miano JM. Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol. 2003;35:577-593.
19. Wang D, Chang PS, Wang Z, Sutherland L, Richardson JA, Small E, Krieg PA, Olson EN. Activation of cardiac gene expression by myo-cardin, a transcriptional cofactor for serum response factor. Cell. 2001;105:851-862.
20. Chen J, Kitchen CM, Streb JW, Miano JM. Myocardin: a component of a molecular switch for smooth muscle differentiation. J Mol Cell Cardiol. 2002;34:1345-1356.
21. Du KL, Ip HS, Li J, Chen M, Dandre F, Yu W, Lu MM, Owens GK, Parmacek MS. Myocardin is a critical serum response factor cofactor in the transcriptional program regulating smooth muscle cell differentiation. Mol Cell Biol. 2003;23:2425-2437.
22. Yoshida T, Sinha S, Dandré F, Wamhoff BR, Hoofnagle MH, Kremer BE, Wang DZ, Olson EN, Owens GK. Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes. Circ Res. 2003;92:856-864.
23. Wang C, Cao D, Wang Q, Wang DZ. Synergistic activation of cardiac genes by myocardin and Tbx5. PLoS ONE. 2011;6:e24242.
24. Li S, Wang DZ, Wang Z, Richardson JA, Olson EN. The serum response factor coactivator myocardin is required for vascular smooth muscle development. Proc Natl Acad Sci USA. 2003;100:9366-9370.
25. Huang J, Cheng L, Li J, Chen M, Zhou D, Lu MM, Proweller A, Epstein JA, Parmacek MS. Myocardin regulates expression of contractile genes in smooth muscle cells and is required for closure of the ductus arteriosus in mice. J Clin Invest. 2008;118:515-525.
26. Long X, Bell RD, Gerthoffer WT, Zlokovic BV, Miano JM. Myocardin is suffcient for a smooth muscle-like contractile phenotype. Arterioscler Thromb Vasc Biol. 2008;28:1505-1510.
27. Pipes GC, Sinha S, Qi X, Zhu CH, Gallardo TD, Shelton J, Creemers EE, Sutherland L, Richardson JA, Garry DJ, Wright WE, Owens GK, Olson EN. Stem cells and their derivatives can bypass the requirement of myocardin for smooth muscle gene expression. Dev Biol. 2005;288: 502-513.
28. Hendrix JA, Wamhoff BR, McDonald OG, Sinha S, Yoshida T, Owens GK. 5' CArG degeneracy in smooth muscle alpha-actin is required for injury-induced gene suppression in vivo. J Clin Invest. 2005;115:418-427.
29. Tharp DL, Wamhoff BR, Turk JR, Bowles DK. Upregulation of intermediate-conductance Ca2+-activated K+ channel (IKCa1) mediates pheno-typic modulation of coronary smooth muscle. Am J Physiol Heart Circ Physiol. 2006;291:H2493-H2503.
30. Wang DZ, Li S, Hockemeyer D, Sutherland L, Wang Z, Schratt G, Richardson JA, Nordheim A, Olson EN. Potentiation of serum response factor activity by a family of myocardin-related transcription factors. Proc Natl Acad Sci USA. 2002;99:14855-14860.
31. Guettler S, Vartiainen MK, Miralles F, Larijani B, Treisman R. RPEL motifs link the serum response factor cofactor MAL but not myocardin to Rho signaling via actin binding. Mol Cell Biol. 2008;28:732-742.
32. Miralles F, Posern G, Zaromytidou AI, Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell. 2003;113:329-342.
33. Olson EN, Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol. 2010; 11:353-365.
34. Mack CP, Somlyo AV, Hautmann M, Somlyo AP, Owens GK. Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. J Biol Chem. 2001;276:341-347.
35. Hinson JS, Medlin MD, Lockman K, Taylor JM, Mack CP. Smooth muscle cell-specifc transcription is regulated by nuclear localization of the myocardin-related transcription factors. Am J Physiol Heart Circ Physiol. 2007;292:H1170-H1180.
36. Lagna G, Ku MM, Nguyen PH, Neuman NA, Davis BN, Hata A. Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors. J Biol Chem. 2007;282:37244-37255.
37. Lockman K, Hinson JS, Medlin MD, Morris D, Taylor JM, Mack CP. Sphingosine 1-phosphate stimulates smooth muscle cell differentiation and proliferation by activating separate serum response factor co-factors. J Biol Chem. 2004;279:42422-42430.
38. Jeon ES, Park WS, Lee MJ, Kim YM, Han J, Kim JH. A Rho kinase/myocardin-related transcription factor-A-dependent mechanism underlies the sphingosylphosphorylcholine-induced differentiation of mes-enchymal stem cells into contractile smooth muscle cells. Circ Res. 2008;103:635-642.
39. Kocher O, Madri JA. Modulation of actin mRNAs in cultured vascular cells by matrix components and TGF-beta 1. In Vitro Cell Dev Biol. 1989;25:424-434.
40. Björkerud S. Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro. Arterioscler Thromb. 1991;11: 892-902.
41. Hirschi KK, Rohovsky SA, D'Amore PA. PDGF, TGF-beta, and hetero-typic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol. 1998;141:805-814.
42. Shah NM, Groves AK, Anderson DJ. Alternative neural crest cell fates are instructively promoted by TGFbeta superfamily members. Cell. 1996;85:331-343.
43. Grainger DJ, Metcalfe JC, Grace AA, Mosedale DE. Transforming growth factor-beta dynamically regulates vascular smooth muscle differentiation in vivo. J Cell Sci. 1998;111 (Pt 19):2977-2988.
44. Deaton RA, Su C, Valencia TG, Grant SR. Transforming growth factor-beta1-induced expression of smooth muscle marker genes involves activation of PKN and p38 MAPK. J Biol Chem. 2005;280: 31172-31181.
45. Ninomiya K, Takahashi A, Fujioka Y, Ishikawa Y, Yokoyama M. Transforming growth factor-beta signaling enhances transdifferen-tiation of macrophages into smooth muscle-like cells. Hypertens Res. 2006;29:269-276.
46. Kennard S, Liu H, Lilly B. Transforming growth factor-beta (TGF-1) down-regulates Notch3 in fbroblasts to promote smooth muscle gene expression. J Biol Chem. 2008;283:1324-1333.
47. Tang Y, Yang X, Friesel RE, Vary CP, Liaw L. Mechanisms of TGF-β-induced differentiation in human vascular smooth muscle cells. J Vasc Res. 2011;48:485-494.
48. Li HX, Han M, Bernier M, Zheng B, Sun SG, Su M, Zhang R, Fu JR, Wen JK. Krüppel-like factor 4 promotes differentiation by transforming growth factor-beta receptor-mediated Smad and p38 MAPK signaling in vascular smooth muscle cells. J Biol Chem. 2010;285:17846-17856.
49. Martin-Garrido A, Brown DI, Lyle AN, Dikalova A, Seidel-Rogol B, Lassègue B, San Martín A, Griendling KK. NADPH oxidase 4 mediates TGF-β-induced smooth muscle α-actin via p38MAPK and serum response factor. Free Radic Biol Med. 2011;50:354-362.
50. Jaffe M, Sesti C, Washington IM, Du L, Dronadula N, Chin MT, Stolz DB, Davis EC, Dichek DA. Transforming growth factor-β signaling in myogenic cells regulates vascular morphogenesis, differentiation, and matrix synthesis. Arterioscler Thromb Vasc Biol. 2012;32:e1-11.
51. Long X, Miano JM. Transforming growth factor-beta1 (TGF-beta1) utilizes distinct pathways for the transcriptional activation of microRNA 143/145 in human coronary artery smooth muscle cells. J Biol Chem. 2011;286:30119-30129.
52. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 2007;1773:1358-1375.
53. Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood fow. Arterioscler Thromb Vasc Biol. 1997;17:2238-2244.
54. Korshunov VA, Berk BC. Flow-induced vascular remodeling in the mouse: a model for carotid intima-media thickening. Arterioscler Thromb Vasc Biol. 2003;23:2185-2191.
55. Nanda V, Miano JM. Leiomodin 1, a new serum response factor-dependent target gene expressed preferentially in differentiated smooth muscle cells. J Biol Chem. 2012;287:2459-2467.
56. Pipes GC, Creemers EE, Olson EN. The myocardin family of transcrip-tional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev. 2006;20:1545-1556.
57. Evelyn CR, Wade SM, Wang Q, Wu M, Iñiguez-Lluhí JA, Merajver SD, Neubig RR. CCG-1423: a small-molecule inhibitor of RhoA transcrip-tional signaling. Mol Cancer Ther. 2007;6:2249-2260.
58. Miano JM, Cserjesi P, Ligon KL, Periasamy M, Olson EN. Smooth muscle myosin heavy chain exclusively marks the smooth muscle lineage during mouse embryogenesis. Circ Res. 1994;75:803-812.
59. Hirschi KK, Lai L, Belaguli NS, Dean DA, Schwartz RJ, Zimmer WE. Transforming growth factor-beta induction of smooth muscle cell phe-notpye requires transcriptional and post-transcriptional control of serum response factor. J Biol Chem. 2002;277:6287-6295.
60. Xie WB, Li Z, Miano JM, Long X, Chen SY. Smad3-mediated myo-cardin silencing: a novel mechanism governing the initiation of smooth muscle differentiation. J Biol Chem. 2011;286:15050-15057.
61. Davis-Dusenbery BN, Chan MC, Reno KE, Weisman AS, Layne MD, Lagna G, Hata A. down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphoge-netic protein 4. J Biol Chem. 2011;286:28097-28110.
62. Hayashi K, Takahashi M, Kimura K, Nishida W, Saga H, Sobue K. Changes in the balance of phosphoinositide 3-kinase/protein kinase B (Akt) and the mitogen-activated protein kinases (ERK/p38MAPK) determine a phenotype of visceral and vascular smooth muscle cells. J Cell Biol. 1999;145:727-740.
63. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A, Cotten M, Daub H. An eff-cient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA. 2003;100:15434-15439.
64. Yakymovych I, Engström U, Grimsby S, Heldin CH, Souchelnytskyi S. Inhibition of transforming growth factor-beta signaling by low molecular weight compounds interfering with ATP-or substrate-binding sites of the TGF beta type I receptor kinase. Biochemistry. 2002;41:11000-11007.
65. Sakamoto K, Murata T, Chuma H, Hori M, Ozaki H. Fluvastatin prevents vascular hyperplasia by inhibiting phenotype modulation and proliferation through extracellular signal-regulated kinase 1 and 2 and p38 mitogen-activated protein kinase inactivation in organ-cultured artery. Arterioscler Thromb Vasc Biol. 2005;25:327-333.
66. Chen S, Qiong Y, Gardner DG. A role for p38 mitogen-activated protein kinase and c-myc in endothelin-dependent rat aortic smooth muscle cell proliferation. Hypertension. 2006;47:252-258.
67. Proctor BM, Jin X, Lupu TS, Muglia LJ, Semenkovich CF, Muslin AJ. Requirement for p38 mitogen-activated protein kinase activity in neointima formation after vascular injury. Circulation. 2008;118:658-666.